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Abstract
Background: Skin and soft tissue infections (SSTIs) are common in the era of community-associated methicillin
resistant Staphylococcus aureus among HIV-infected patients. Recurrent infections are frequent. Risk factors for
recurrence after an initial SSTI have not been well-studied.
Methods: Retrospective cohort study, single center, 2005–2009. Paper and electronic medical records were
reviewed by one of several physicians. Subjects with initial SSTI were followed until the time of SSTI recurrence.
Standard descriptive statistics were calculated to describe the characteristics of subjects who did and did not
develop a recurrent SSTI. Kaplan-Meier methods were used to estimate the risk of recurrent SSTI. A Cox regression
model was developed to identify predictors of SSTI recurrence.
Results: 133 SSTIs occurred in 87 individuals. 85 subjects were followed after their initial SSTI, of whom 30 (35.3 %)
had a recurrent SSTI in 118.3 person-years of follow-up, for an incidence of second SSTI of 253.6 SSTIs/1000
person-years (95 % CI 166.8-385.7). The 1-year Kaplan-Meier estimated risk of a second SSTI was 29.2 % (95 % CI
20.3–41.0 %), while the 3-year risk was 47.0 % (95 % CI 34.4–61.6 %). Risk factors for recurrent SSTI in a multivariable
Cox regression model were non-hepatitis liver disease (HR 3.44; 95 % CI 1.02–11.5; p = 0.05), the presence of an
intravenous catheter (HR 6.50; 95 % CI 1.47–28.7; p = 0.01), and a history of intravenous drug use (IVDU) (HR 2.80;
95 % CI 1.02-7.65; p = 0.05); African-American race was associated with decreased risk of recurrent SSTI (HR 0.12;
95 % CI 0.04-0.41; p < 0.01). Some evidence was present for HIV viral load ≥ 1000 copies/mL as an independent risk
factor for recurrent SSTI (HR 2.21; 95 % CI 0.99-4.94; p = 0.05). Hemodialysis, currently taking HAART, CD4+ count,
trimethoprim-sulfamethoxazole or azithromycin use, initial SSTI type, diabetes mellitus, incision and drainage of the
original SSTI, or self-report of being a man who has sex with men were not associated with recurrence.
Conclusion: Of HIV-infected patients with an SSTI, nearly 1/3 had a recurrent SSTI within 1 year. Risk factors for
recurrent SSTI were non-hepatitis liver disease, intravenous catheter presence, a history of IVDU, and
non-African-American race. Low CD4+ count was not a significant risk factor for recurrence.
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Background
In 1998, the first increase in incidence of methicillin resist-
ant Staphylococcus aureus (MRSA) infections in people
without previous contact with the health care system was
reported in children in Chicago [1]. Community-associated
(CA-MRSA) infections were subsequently identified in
other groups in the United States, especially marginalized
populations, and CA-MRSA quickly became the leading
cause of skin and soft tissue infections (SSTIs) with com-
munity onset among incarcerated populations and among
impoverished urban populations [2, 3]. The advent of the
CA-MRSA era dramatically affected the epidemiology of
SSTIs, with a doubling in the number of SSTIs seen at
safety net hospital emergency rooms [2].
Patients with human immunodeficiency virus (HIV)
infection are particularly prone to infection with CA-
MRSA because they are immunocompromised and
because of demographic, behavioral, and socioeconomic
factors as well as frequent exposures to the health care
system [4, 5]. We have recently evaluated risk factors for
a first SSTI among 511 HIV-infected patients in Chicago
[6]. In that study, accounting for follow-up time, chronic
skin conditions such as psoriasis and lymphedema, pres-
ence of an intravenous catheter, and lack of virologic
suppression were most strongly associated with initial
SSTI occurrence. There was also a trend toward an in-
creased risk of SSTI in subjects receiving health insurance
through Medicaid, the governmental health insurance
program for the poor and disabled, and subjects with
sexually transmitted diseases (STDs). Other studies have
identified different risk factors [4], though our study
differed methodologically from many other studies in that
we identified all SSTIs which were documented in the
medical record, not just SSTIs which were culture positive
for S. aureus. This is important because in our study we
found that cultures were more likely to be sent during an
SSTI episode in patients with advanced immunocompro-
mise [6]. Therefore, relying on culture data as a criterion
for detection of an SSTI in retrospective studies may lead
to biased conclusions about the epidemiology of SSTIs in
the HIV-infected population. Although a number of anec-
dotal reports have suggested that recurrent SSTIs are
common among HIV-infected patients [7, 8], few studies
have examined the incidence of and risk factors for recur-
rent SSTIs in the HIV-infected population in the current
era of CA-MRSA [9–12]. Accordingly, we set out to
examine the risk factors for SSTI recurrence in an HIV-
infected population receiving care at an urban tertiary care
center clinic in the CA-MRSA era.
Methods
Study design
We performed a retrospective study of 511 HIV-infected
adults (>18 years of age) who received their primary
HIV care at the University of Chicago Medical Center’s
(UCMC) Infectious Diseases Clinic for any period of
time between January 1, 2005 and December 31, 2009. A
description of this cohort has previously been published
elsewhere [6]. SSTI was defined based on a physician diag-
nosis identified in medical record review. Recurrent SSTI
was defined as either an SSTI at a new site or recurrence
at the original site greater than 30 days after the initial
SSTI with resolution of the signs and symptoms of the ori-
ginal infection in the interim. Individuals eligible for this
study were those in the cohort who developed an SSTI and
who accrued further follow-up time in the clinic after the
initial SSTI. Subjects contributed follow-up time to this
study from the day after the initial SSTI until either the
occurrence of a first SSTI recurrence or until censoring.
The study was approved by the Institutional Review Board
of the Biological Sciences Division of the University of
Chicago. Requirement for informed consent was waived.
Statistical methods
Proportions between groups were compared by the χ2 or
Fisher’s exact test, as appropriate (i.e. if any cell in the
appropriate 2 x N categorical table contained five or
fewer subjects). Differences between groups of continu-
ous outcomes were compared using the t-test or the
Wilcoxon rank-sum test. Cox regression was used for
time-to event data to calculate the hazard ratio (HR)
with 95 % confidence interval (CI) associated with
various patient characteristics [13]. The overall fit of po-
tential Cox models was assessed via a plot of the
Nelson-Aalen cumulative hazard against Cox-Snell re-
siduals [14, 15]. The proportional hazards assumption
was verified in potential models via the use of log-log
plots, and the presence or lack of influential observa-
tions was verified by calculating DFBETAs for each
potential predictor [15]. Incidence rates were calculated
using cluster-adjusted Poisson regression [16]. Based on
exploratory analysis, we chose to categorize viral load as
a binary variable with cutoff of 1000 copies/mL. CD4+
count was similarly categorized as a binary variable with
cutoff of 100 cells/mL. Patients who had greater than
365 days without a measured CD4+ count or HIV viral
load (VL) were deemed to have been lost to follow-up
for that period and were interval censored in the statis-
tical analysis [17].




Of the 511 subjects in the initial cohort, 87 individuals
(17.0 %) experienced at least one SSTI, as described else-
where [6]. Two subjects from the cohort had no follow-
up time after the initial SSTI, so 85 subjects were
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included in the analysis reported in this study. The
demographics of this cohort are shown in Table 1. The
85 subjects contributed 118.3 person-years of follow-up,
with subjects censored at loss to follow-up or at the time
of recurrent SSTI.
Of the initial SSTIs, 50 (58.8 %) were abscesses, 27
(31.8 %) were furuncles, and 8 (9.4 %) were cellulitides.
Incision and drainage of the initial SSTI was performed in
28 cases (32.9 %). Only 23/85 initial SSTIs were associated
with culture data, one of which was culture-negative. S.
aureus was an identified pathogen in 15 initial SSTIs, and
MRSA in 11 of these. Pseudomonas aeruginosa was the
only other pathogen identified in more than one patient,
having been identified in 3 SSTIs. All cultures were from
an infected skin site.
Of the 85 initial SSTIs, 20 (23.5 %) were treated with
combination antimicrobial drug therapy. The most com-
mon combination used was ciprofloxacin and clindamy-
cin, used in 3 patients (3.5 % of all patients, 15 % of
patients receiving combination therapy). Of the 65 who
did not receive combination antimicrobial drug therapy,
20 (23.5 % of all initial SSTIs) received a beta-lactam, 21
(24.7 %) received clindamycin, 8 (9.4 %) received
trimethoprim-sulfamethoxazole, 5 (5.9 %) received a
fluoroquinolone, 2 (2.4 %) received vancomycin, and 3
(3.5 %) received no antimicrobial drug therapy. Whether
or not antimicrobial drug therapy was prescribed for the
initial SSTI was not documented in the medical records
of six (7.1 %) patients. As documented in the medical
record, no subject underwent attempts at decolonization
after the initial SSTI.
A total of 30 subjects among the 85 who had follow-up
(35.3 %) experienced at least one recurrent SSTI during
follow-up. Using Kaplan-Meier methods, the estimated
proportion of individuals who would have experienced a
recurrent SSTI if all individuals had been followed for one
year was 29.2 % (95 % CI 20.3 %-41.0 %), while the 3-year
risk was 47.0 % (95 % CI 34.4 %-61.6 %). Figure 1 shows
the estimated Kaplan-Meier cumulative incidence of
SSTIs over time. The incidence of second SSTI was 253.6
SSTIs/1000 person-years (95 % CI 166.8-385.7). Fourteen
subjects experienced multiple recurrences (16.5 % of all
subjects with initial SSTI; 46.7 % of subjects with at least
one recurrence).
A number of variables assessed as potential risk factors
for SSTIs were time-varying. These variables were there-
fore not assumed to be present throughout the follow-
up period; instead, they were calculated as present or
absent on each day of follow-up. For example, 79.8 % of
follow-up time accrued to individuals on Medicaid,
1.6 % to individuals with a catheter, 24.7 % to individuals
taking trimethoprim-sulfamethoxazole prophylaxis, and
12.0 % to individuals taking azithromycin prophylaxis.
Highly active antiretroviral therapy (HAART) was being
given 77.1 % of the time, and the cohort had an HIV VL
< 1000 copies/mL on 60.0 % of days. The diagnosis of
certain comorbid conditions was assessed similarly, with
14.6 % of follow-up time occurring in subjects with dia-
betes, and 7.8 % with cancer (Table 2).
Characteristics of recurrent SSTIs
The median recurrent SSTI occurred at 144 days after
the initial SSTI (interquartile range [IQR], 89–377).
Trimethoprim-sulfamethoxazole prophylaxis was being
taken by 5/30 subjects (16.7 %) at the time of SSTI, and 3/6
(50 %) individuals with CD4+ count < 200 cells/mm3 at the
time of SSTI were taking trimethoprim-sulfamethoxazole.
The median CD4+ count at the time of recurrent SSTI was
403.5 (IQR 239–529), and the median VL was 1475 copies/
mL (IQR undetectable-27800). We found that 26/30
(86.7 %) SSTI recurrences occurred in patients with CD4+
count > 100 cells/mm3. Of the recurrent infections, 17 were
abscesses (56.7 %), 9 were cellulitis (30.0 %), and 3 were
furuncles (10.0 %), and the type of SSTI was undocumented
in one case. 13 of 30 (43.3 %) recurrent infections met
Centers for Disease Control and Prevention (CDC) criteria
for a community-associated SSTI (CA-SSTI) [18]. The
primary reason that an SSTI was not classified as a CA-
SSTI was hospitalization within the prior year, which was
the case in 12/30 (40.0 %) patients.
Culture data were only obtained for 8 of the recurrent
SSTIs, and of those, 6 of the 8 (75 %) were confirmed S.
aureus infections, with 4 of the 6 (67 %) being MRSA.
Of those 4 infections, 3 were clindamycin-susceptible
MRSA, and all four were susceptible to trimethoprim-
sulfamethoxazole. Of the 6 culture-proven S. aureus
infections, only 1 MRSA SSTI met CDC criteria for
being a CA-SSTI. The other two SSTIs were caused by
Proteus and a coagulase negative staphylococcus species.
Three of the six recurrent SSTIs caused by S. aureus
were associated with culture data for the initial SSTI; all
three initial SSTIs were caused by S. aureus as well. In
two patients, both infections were causes by MRSA, and
in one patient, both infections were causes by MSSA.
Therapy in cases of recurrent SSTI was with a beta-
lactam in five cases (16.7 %), combination therapy in
seven cases (23.3 %), clindamycin in four cases (13.3 %),
TMP-SMX in three cases (10 %), levofloxacin in one
case (3.3 %), and vancomycin in one case (3.3 %). Five
patients (16.7 %) received no systemic antibacterial ther-
apy, and antibiotic therapy was not documented in four
cases (13.3 %).
Predictors of Recurrent SSTI
The results of univariate Cox regression with possible pre-
dictors of SSTI are listed in Table 3. At any given time
point, the presence of an intravascular catheter (HR 4.62;
95 % confidence intervals [CI] 1.08-19.7; p = 0.04), chronic
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Table 1 Baseline characteristics of individuals who did and did not develop a recurrent SSTI during the study period
Baseline variable No recurrent SSTI (n = 55) Had recurrent SSTI (n = 30) Total (n = 85)
Sex
Male 30 (65.2 %) 16 (34.8 %) 46 (54.1 %)
Female 25 (64.1 %) 14 (35.9 %) 39 (45.9 %)
Sexual behavior
Male 30 (65.2 %) 16 (34.8 %) 46
Sex with men and women 6 (75.0 %) 2 (25.0 %) 8 (17.4 %)
Sex with men 11 (64.7 %) 6 (35.3 %) 17 (36.7 %)
Sex with women 13 (61.9 %) 8 (38.1 %) 21 (45.7 %)
Female 25 (64.1 %) 14 (35.9 %) 39
Sex with women 1 (100 %) 0 (0 %) 1 (2.6 %)
Sex with men 24 (63.2 %) 14 (36.8 %) 38 (97.4 %)
Mean initial age (sd) 40.7 (1.5) 40.1 (1.9) 40.5 (1.2)
Median initial CD4 (IQR) 363 (180–553) 351 (242–542) 353 (199–552)
Initial VL at time of first SSTI
<1000 28 (70.0 %) 12 (30.0 %) 40 (47.1 %)
1000+ 27 (60.0 %) 18 (40.0 %) 45 (52.9 %)
IVDU history
No 49 (67.1 %) 24 (32.9 %) 73 (86.9 %)
Yes 5 (45.4 %) 6 (54.6 %) 11 (13.1 %)
Inhaled drug use
No 41 (64.1 %) 23 (35.9 %) 64 (76.2 %)
Yes 13 (65.0 %) 7 (35.0 %) 20 (23.8 %)
Methamphetamine use
No 54 (65.1 %) 29 (35.9 %) 83 (98.8 %)
Yes 0 (0 %) 1 (100 %) 1 (1.2 %)
Incarceration
No 47 (61.8 %) 29 (38.2 %) 76 (90.5 %)
Yes 7 (87.5 %) 1 (12.5 %) 8 (9.5 %)
Race
African-American 52 (67.5 %) 25 (32.5 %) 77 (91.7 %)
Caucasian 2 (40.0 %) 3 (60.0 %) 5 (5.9 %)
Hispanic 1 (50.0 %) 1 (50.0 %) 2 (2.4 %)
Educational status
Did not complete high school 5 (83.3 %) 1 (16.7 %) 6 (22.2 %)
High school graduate 1 (33.3 %) 2 (66.7 %) 3 (11.1 %)
Some college 8 (66.7 %) 4 (33.3 %) 12 (44.4 %)
College graduate 4 (66.7 %) 2 (33.3 %) 6 (22.2 %)
Employment during follow-up
No 32 (64.0 %) 18 (36.0 %) 50 (59.5 %)
Yes 22 (64.7 %) 12 (35.3 %) 34 (40.5 %)
Chronic skin disease
No 38 (69.1 % 17 (30.9 %) 55 (64.7 %)
Yes 17 (56.7 %) 13 (43.3 %) 30 (35.3 %)
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Table 1 Baseline characteristics of individuals who did and did not develop a recurrent SSTI during the study period (Continued)
Hepatitis C
No 47 (64.4 %) 26 (35.6 %) 73 (85.9 %)
Yes 8 (66.7 %) 4 (33.3 %) 12 (14.1 %)
Non-hepatitis liver disease
No 54 (67.5 %) 26 (32.5 %) 80 (94.1 %)
Yes 1 (20.0 %) 4 (80.0 %) 5 (5.9 %)
Initial SSTI type
Abscess 28 (56.0 % 22 (44.0 %) 50 (58.8 %)
Furuncle 20 (74.1 %) 7 (25.9 %) 27 (31.8 %)
Cellulitis 7 (87.5 %) 1 (12.5 %) 8 (9.4 %)
Incision and drainage performed
No 41 (71.9 %) 16 (28.1 %) 57 (67.1 %)
Yes 14 (50.0 %) 14 (50.0 %) 28 (32.9 %)
Initial SSTI S aureus
No 48 (68.6 %) 22 (31.4 %) 70 (82.4 %)
Yes 7 (46.7 %) 8 (26.7 %) 15 (17.7 %)
Initial SSTI MRSA
No 50 (67.6 %) 24 (32.4 %) 74 (87.1 %)
Yes 5 (45.5 %) 6 (54.5 %) 11 (12.9 %)
Initial SSTI Treatment
Combination therapy 11 (55.0 %) 9 (45.0 %) 20 (23.5 %)
Beta-lactam 12 (60.0 %) 8 (40.0 %) 20 (23.5 %)
Clindamycin 16 (76.2 %) 5 (23.8 %) 21 (24.7 %)
Fluoroquinolone 4 (80.0 %) 1 (20.0 %) 5 (5.9 %)
Trimethoprim- sulfamethoxazole 5 (62.5 %) 3 (37.5 %) 8 (9.4 %)
Vancomycin 2 (100 %) 0 (0 %) 2 (2.3 %)
None 3 (100 %) 0 (0 %) 3 (3.5 %)
Unknown 2 (33.3 %) 4 (66.7 %) 6 (7.1 %)
Chlamydia since 2004
No 52 (64.2 %) 29 (35.8 %) 81 (95.3 %)
Yes 3 (75.0 %) 1 (25.0 %) 4 (4.7 %)
Gonorrhea since 2004
No 54 (65.1 %) 29 (34.9 %) 83 (97.7 %)
Yes 1 (50.0 %) 1 (50.0 %) 2 (2.3 %)
Syphilis since 2004
No 50 (63.3 %) 29 (36.7 %) 79 (92.9 %)
Yes 5 (83.3 %) 1 (16.7 %) 6 (7.1 %)
Human papilloma virus (Clinical) since 2004
No 47 (65.3 %) 25 (34.7 %) 72 (84.7 %)
Yes 8 (61.5 %) 5 (38.5 %) 13 (15.3 %)
Human papilloma virus (Pap) since 2004
No 45 (64.3 %) 25 (35.7 %) 70 (82.4 %)
Yes 10 (66.7 %) 5 (33.3 %) 15 (27.6 %)
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Table 1 Baseline characteristics of individuals who did and did not develop a recurrent SSTI during the study period (Continued)
Trichomonas since 2004
No 47 (61.8 %) 29 (38.2 %) 76 (89.4 %)
Yes 8 (88.9 % 1 (11.1 %) 9 (10.6 %)
Any sexually transmitted disease since 2004
No 29 (59.2 %) 20 (40.8 %) 49 (57.7 %)
Yes 26 (72.2 %) 10 (27.8 %) 36 (42.4 %)
Pneumocystic jirovecii since 2004
No 54 (65.8 %) 28 (34.2 %) 82 (96.5 %)
Yes 1 (33.3 %) 2 (66.7 %) 3 (3.5 %)
Non-tuberculous mycobacteria since 2004
No 53 (63.9 %) 30 (36.1 %) 83 (97.7 %)
Yes 2 (100.0 %) 0 (0.0 %) 2 (2.4 %)
Cytomegalovirus since 2004
No 54 (64.3 %) 30 (35.7 %) 84 (98.8 %)
Yes 1 (100.0 %) 0 (0.0 %) 1 (1.2 %)
Cryptococcus since 2004
No 53 (64.6 %) 29 (35.4 %) 82 (96.5 %)
Yes 2 (66.7 %) 1 (33.3 %) 3 (3.5 %)
Initial TMP-SMX use
No 41 (65.1 %) 22 (34.9 %) 63 (74.1 %)
Yes 14 (63.6 %) 8 (36.4 %) 22 (25.9 %)
Initial azithromycin use
No 48 (63.2 %) 28 (36.8 %) 76 (89.4 %)
Yes 7 (77.8 %) 2 (22.2 %) 9 (10.6 %)
Initial HAART use
No 13 (52.0 %) 12 (48.0 %) 25 (29.4 %)
Yes 42 (70.0 %) 18 (30.0 %) 60 (70.6 %)
Initial catheter presence
No 54 (65.9 %) 28 (34.1 %) 82 (96.5 %)
Yes 1 (33.3 %) 2 (66.7 %) 3 (3.5 %)
Initial insurance Medicaid
No 16 (64.0 %) 9 (36.0 %) 25 (29.4 %)
Yes 39 (65.0 %) 21 (35.0 %) 60 (70.6 %)
Initial cancer status
No 50 (63.3 %) 29 (36.7 %) 79 (92.9 %)
Yes 5 (83.3 %) 1 (16.7 %) 6 (7.1 %)
Initial diabetes
No 48 (65.8 %) 25 (34.3 %) 73 (85.9 %)
Yes 7 (58.3 %) 5 (41.7 %) 12 (14.1 %)
Initial ESRD status
No 48 (65.8 %) 25 (34.3 %) 73 (85.9 %)
Yes 7 (58.3 %) 5 (41.7 %) 12 (14.1 %)
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liver disease (HR 2.89; 95 % CI 1.00-8.35, p = 0.05), and
lymphedema (HR 4.12; 95 % CI 1.24-14.1; p = 0.02) were
associated with an increased risk of recurrent SSTI, while
African-American race was associated with decreased risk
of recurrent SSTI (HR 0.34; 95 % CI 0.11-1.00; p = 0.05).
Predictors with p < 0.2 were candidates for the final
multivariate Cox model, which was developed by a for-
ward selection algorithm. Significant predictors as well
as theoretical concerns led to the choice of our final
model for multivariate regression. For example, we found a
strong association between lymphedema and intravenous
drug use (IVDU) in our cohort; we accordingly only in-
cluded IVDU in the final model to avoid collinearity.
Similarly, although gonorrhea was a strong statistical pre-
dictor of recurrent SSTI in several preliminary multivariate
models, we found that models including gonorrhea were
overly influenced by the single subject with a history of
gonorrhea during follow up with recurrent SSTI (out of
two subjects with a history of gonorrhea during follow up).
Accordingly, gonorrhea was not included in the final
model as it was felt that the data were inadequate to allow
for a multivariable analysis including this predictor. Risk
factors for recurrent SSTI in the final multivariable Cox
regression model were non-hepatitis liver disease (HR 3.44;
95 % CI 1.02-11.5; p = 0.05), the presence of an intravenous
catheter (HR 6.50; 95 % CI 1.47-28.7; p = 0.01), and a his-
tory of intravenous drug use (HR 2.80; 95 % CI 1.02-7.65;
p = 0.05); African-American race remained associated with
a decreased risk (HR 0.17; 95 % CI 0.05-0.54; p < 0.01). A
trend was present for HIV viral load ≥1000 copies/mL as
an independent risk factor for recurrent SSTI (HR 2.21;
95 % CI 0.99-4.94; p = 0.05), which was nearly statistically
significant. A Cox-Snell residual plot demonstrated that
the model fit the data well (plot not shown).
As a sensitivity analysis, we repeated the above ana-
lyses but used 30-, 60-, 90- and 365-day recent averages
for a number of the above time-varying factors, without
significant change in the results (data not shown). Simi-
larly, we used linearly extrapolated CD4+ counts and
HIV VLs and found that point estimates did not change
significantly. As a final sensitivity analysis, we used CD4
+ count of 200 as an alternative cutoff, without signifi-
cant change in the results.
Discussion
In an urban, primarily African-American cohort, we
confirmed that patients infected with HIV who had a
medically attended SSTI had a high rate of subsequent
SSTI, with most recurrences diagnosed within months
Fig. 1 Kaplan-Meier curve demonstrating the cumulative risk of recurrent SSTI over time with 95 % confidence intervals
Table 2 Proportion of patient-days with exposure to time-
varying covariates






Public Aid 79.8 %
Viral load
<1000 copies/mL 60.0 %
1000+ copes/mL 40.0 %
CD4
<50 cells/mL 6.5 %
50–99 cells/mL 4.0 %
100+ cells/mL 89.5 %
Cancer 7.8 %
Diabetes 14.6 %
End-stage renal disease 11.5 %
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of the initial SSTI. We identified risk factors for recur-
rence which do not entirely overlap the risk factors for
initial SSTI found in our previous paper [19] or in the
work of others [20], though our studies differed from
most other studies in examining all subjects with SSTIs,
not just those with proven MRSA SSTIs. It may be that
the risk factors for initial SSTI occurrence differ from
those that predispose to continued colonization with or
re-exposure to pathogenic bacteria.
In our cohort, African Americans, who constituted
more than 90 % of the patient sample, demonstrated a
significantly lower rate of recurrent SSTI as compared
with others. We surmise that the risk factors leading to
initial SSTIs in those not of African-American descent
in our cohort may be more strongly associated with the
risk of SSTI recurrence than the risk factors leading to
initial SSTI in African Americans. However, our sample
of non-African Americans is too small to permit rigor-
ous testing of this hypothesis. Previous observational co-
horts have noted that African-Americans are less likely
to remain in care [21], but differential rates of follow-up
for African-Americans would only explain our results if
African Americans having recurrent SSTIs were more
likely than other African Americans to be lost to follow-
up. We also found that established risk factors for SSTI
recurrence such as intravenous drug use and presence of
an intravenous catheter [8] predicted SSTI recurrence.
Some of our preliminary modelling suggested an inde-
pendent impact of a gonorrhea diagnosis, although the
STD incidence observed in our population was too low
to assess reliably the effect of STD diagnosis on SSTI re-
currence risk. It has been proposed that ongoing high
risk sexual behavior may re-expose HIV-infected pa-
tients to pathogenic strains of MRSA. Prior studies by
other researchers have found that many HIV-infected
Table 3 Predictors of risk of recurrent SSTI in univariate and
multivariate Cox regression models
Factor Univariate HR p-value Multivariate HR
(Final model)
p-value
(95 % CI) (95 % CI)




Azithromycin 1.38 (0.48–3.98) 0.55
Age (cont) 0.99 (0.96–1.03) 0.71
STD (any) 1.06 (0.49–2.27) 0.88
Chlamydia 1.18 (0.16–8.77) 0.87
Gonorrhea 4.96 (0.65–37.7) 0.12









Trichomonas 0.45 (0.06–3.33) 0.44
Catheter 4.62 (1.08–19.7) 0.04 6.50 (1.47–28.7) 0.01




Cancer 0.51 (0.07–3.73) 0.51
Diabetes 1.03 (0.39–2.69) 0.96




Incarceration 0.22 (0.03–1.65) 0.14
Other chronic
liver disease





IVDU 2.41 (0.98–5.91) 0.06 2.80 (1.02-7.65) 0.05






















Table 3 Predictors of risk of recurrent SSTI in univariate and
multivariate Cox regression models (Continued)
Viral load
<1000 Reference Reference
1000+ 1.58 0.22 2.21 (0.99–4.94) 0.05
Initial SSTI type
Abscess Reference
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patients only demonstrate groin colonization with
MRSA without colonization at other sites [22]. The oc-
currence of gonorrhea or other STDs may serve as a
marker of continuing exposure to other colonized indi-
viduals, leading to reacquisition of pathogenic strains
and predisposing towards SSTI recurrence.
We found that non-hepatitis liver disease, which in
our cohort was predominantly due to alcoholic liver dis-
ease, was a risk factor for recurrent SSTI. Although not
previously described specifically as a risk factor for recur-
rent SSTI in HIV-infected populations, the association
between cirrhosis and SSTI risk has been previously de-
scribed by other authors [23].
We were unable to test the finding of others that treat-
ment of the initial SSTI with minocycline reduces the
risk of recurrence [11] because only one patient in our
study received minocycline as the treatment for the initial
SSTI, which reflects institutional preferences for certain
antimicrobials for the treatment of SSTIs at our center.
Our finding that lack of virologic control, better than
CD4+ lymphocyte count per se, predicted SSTI risk is
difficult to explain but is consistent with the findings of
other authors [10]. This effect may be related to the
immunologic effect of uncontrolled HIV replication. Al-
ternatively, unsuppressed viral load, a marker of poor
adherence to medication, may serve as a marker of pa-
tients who are not taking trimethoprim-sulfamethoxazole
prophylaxis to prevent pneumocystis pneumonia, which
potentially may also be protective against SSTI [24, 25].
Alternatively, lack of virologic suppression may be a
marker of other behavioral and demographic risk factors
for SSTI.
Our study is one of only six in which authors have ex-
amined SSTI recurrence in HIV-infected adults (Table 4).
Skiest et al. performed a single-center prospective study
at an urban, public clinic in Dallas, accruing patients with
initial S. aureus skin infection seeking outpatient care in
2003–2004 [12]. Recurrent SSTI was noted in 11/37 pa-
tients (29.7 %). Adjustment for variable length of follow-
up after the initial SSTI was not performed. Whether or
not appropriate antimicrobial therapy was prescribed and
whether or not incision and drainage was performed did
not affect recurrence risk. No additional statistical analysis
of risk factors for recurrence was reported.
Graber et al. performed a single-center retrospective
study at an urban, public clinic in San Francisco, accru-
ing patients with initial MRSA infection seeking out-
patient care in 2002–2006 [9]. Patients were followed
through 2007. A recurrent SSTI occurred in 44/62 pa-
tients (71.0 %). Adjustment for variable length of follow-
up after the initial SSTI was not performed. The median
time to recurrence was 135.5 days, which was similar to
the finding in our study. Cox regression performed on
demographic and clinical predictors did not yield a
significant predictor of SSTI recurrence. Of 62 patients
with an initial MRSA SSTI, 17 (27 %) developed a
recurrence.
Vyas et al. performed a single-center retrospective
study at a military-affiliated HIV clinic in San Diego,
accruing patients with initial MRSA SSTI in 2003–2010
[7, 11]. Patients were followed through 2010. Of 63 pa-
tients with initial MRSA SSTI, 17 (27 %) experienced a
recurrent MRSA SSTI. Adjustment for variable length of
follow-up after the initial SSTI was not performed. The
lower rate of recurrence in this study may have resulted
from the inclusion of only culture-proven recurrences.
Incision and drainage was not associated with a decreased
risk of recurrence. Use of an antibiotic other than minocy-
cline and hospitalization for the initial SSTI were signifi-
cant risk factors for recurrence in a multivariable analysis
(Table 4). Patients with a recurrent SSTI demonstrated a
significantly lower CD4+ count in a mixed-effects model
using CD4+ lymphocyte count as the outcome.
Crum-Cianflone et al. performed a single-center retro-
spective study at a military-affiliated HIV clinic in San
Diego, accruing patients with initial MRSA SSTI in
2000–2007 [10]. This study was performed at the same
center as Vyas’s study in an overlapping time frame. Of 31
patients with initial MRSA SSTI, 14 (41 %) had a recur-
rent SSTI. The proportion of recurrence in this study dif-
fered from that observed in the Vyas study as the outcome
included all SSTIs, not just SSTIs proven to be caused by
MRSA. Median time to recurrence was 4 months, com-
parable to the results of our study. In a multivariable logis-
tic regression model, only HIV VL > 1000 copies/mL was
a significant predictor of recurrence.
Crum-Cianflone et al. examined data from the US
Military HIV Natural History Study, a multicenter pro-
spective cohort study, from 2006 to 2010 [26]. Of 379
subjects with an initial SSTI, 31 % experienced a recur-
rence at a median 7 months after the initial SSTI. They
did not identify a statistically significant risk factor for
recurrent SSTI. However, there was some suggestion in
the data that the presence of a dermatological condition at
the time of diagnosis of the initial SSTI (HR 1.99; 95 % CI
0.95–4.16; p = 0.07) and higher HIV RNA level (HR 1.18
per 10-fold increase in viral load; 95 % CI 0.98–1.43; p =
0.08) may have been associated with recurrence.
Our study was limited as it was a single-center retro-
spective medical record review. Therefore, some demo-
graphic information was missing. The diagnosis and
outcome of SSTI was based on physician documentation.
Older paper records were incomplete. SSTIs diagnosed at
centers other than our own were missed, and so our esti-
mate of SSTI recurrence risk was likely a lower bound.
We have no specific data on how often patients in our
cohort sought care elsewhere. There are community hos-
pitals with emergency departments but no other major
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tertiary care centers within five miles of our center. Cox
regression requires an assumption of non-informative
censoring (i.e., that subjects who are lost to follow-up are
similar in their characteristics to those who remain en-
gaged in care), and the results of our analysis may be
biased to the extent that this assumption is violated. How-
ever, the problem of loss to follow-up is inherent to any
study of urban HIV-infected populations [27].
Conclusions
This study contributes to the literature as one of the few
analyses of risk factors for recurrence of SSTI in an
urban, socioeconomically diverse cohort of HIV-infected
adults. Our study is unique in that most previous studies
on this topic have only included subjects whose initial
SSTIs were culture-proven S. aureus SSTIs, while our
study includes all subjects in our cohort with an initial
SSTI. Our investigation improves on other studies by ex-
plicitly accounting for time-varying predictor variables
and for variable time of follow-up using Kaplan-Meier
methods and by following patients for a relatively long
period of time. Further work to define risk factors for
SSTI recurrence will enable physicians to target poten-
tial preventative interventions to those HIV-infected
individuals at highest risk of SSTI recurrence.
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